Issue 2 · 2026-07-22
RuleCascade — Issue 2 · published 2026-07-22
Imagine negotiating 30% off a new car. The dealer shakes your hand, and then keeps the right to raise the sticker price whenever he likes. You would never sign that deal. Most hospital "negotiated" rates are that deal. At the ten Community Health hospitals whose price files I read end to end, four of five commercial rates work exactly this way.
Here is how it works. Every hospital keeps a master price list called the chargemaster. The hospital writes it, and the hospital can raise it any day it chooses. So when an insurance contract says "we pay 62% of billed charges," the payment tracks a number the hospital controls. Raise the list 9%, and the payment rises 9%. Nobody renegotiated anything.
If you work in healthcare, the mechanism is old news. Economists were calling hospital pricing "chaos behind a veil of secrecy" back in 2006, and everyone in the industry knows the chargemaster is a work of fiction. Here is what nobody knew: how much revenue actually rides on that fiction, at which operators, hospital by hospital. The contracts were private, so the question had no answer.
Since January, it does. Federal price-transparency rules (45 CFR part 180) require every hospital to publish a machine-readable file of its real negotiated rates, and since January 1, 2026 the required format makes each rate line say which pricing method it uses. I downloaded 29 of those files from the four large for-profit hospital operators and read every line: 31.4 million commercial rates, meaning the prices employer and private insurance plans pay.
Of each operator's disclosed commercial rates, how many track its own chargemaster instead of naming a fixed dollar amount?
| Operator | Rates that track the chargemaster | Hospitals read in full | Lowest to highest hospital |
|---|---|---|---|
| Community Health (CYH) | 81.6% | 10 of ~70 | 45.9% to 94.3% |
| Universal Health (UHS) | 77.2% | 7 acute-care | 53.9% to 92.8% |
| HCA | 40.9% | 10 of ~190 | 2.8% to 60.8% |
| Tenet (THC) | 5.2% | 2 of 10; the other 8 files are empty | 3.6% to 10.7% |
I can find no published estimate of this exposure at any operator. This table appears to be the first count.
A pre-registered short: Community Health, with Universal Health behind it. The short is not open yet, and I am not hedging about why: nothing has repriced a contract. So I am registering it as a standing order instead. The short opens, and goes on the graded record, at the close of the first trading session after any one of three tripwires fires: H.R. 9393 passes a House floor vote; CMS's enforcement list names any major operator; or a top-five insurer publicly announces converting percent-of-charges contracts to fixed rates. Until one fires, no entry. When one fires, no hesitation.
A tilt you can act on immediately: within hospitals, this risk favors HCA and Tenet over Community Health and Universal. Roughly a third of CYH's total revenue and 22% of UHS's reprices off the hospital's own list prices. HCA runs 41% linked but spreads it across about 190 markets, so any single repricing event touches a sliver. The market prices none of this yet, because the market has not read these files. If you hold the hospital group, the same dollar of revenue is safer at HCA than at CYH, and it is currently priced as if it were not.
What the short is worth when it dates: if a quarter of CYH's chargemaster-linked rates convert to fixed rates at a 10% discount, that costs roughly $100 to 115 million a year. That is about 0.9% of revenue, and nearly all of it falls straight to operating earnings. Double the conversion, double the number.
The nearest catalyst just advanced. The Energy & Commerce Committee approved H.R. 9393, as amended, by 45 to 0 on July 21, 2026. A committee vote is not a floor vote, so the standing order stays unopened; the bill now waits on House floor scheduling. The open HCA long stays on, down 11 points, graded in public below.
Dates: HCA earnings July 24; outpatient-rule comments close August 31; final payment rules around November; committee-to-floor progress on H.R. 9393 whenever the House schedules it.
I read every file that came back readable from each operator's own published index; that made 29. Ten hospitals of Community Health's seventy is a sample, so the honest company-level statement is a range, and the table's last column is that range. Notice the floor: the lowest Community Health hospital I read still writes 45.9% of its commercial rates against the chargemaster. HCA is a different animal. Its hospitals run from 2.8% to 60.8%, which tells you HCA decides this market by market.
Don't take my word for any of this. Laredo Medical Center's file is public. It contains 593,004 commercial rate lines, and 559,391 of them price as a percentage of charges. Divide the two numbers and you get 94.3%, the top of the Community Health range.
One warning for anyone who reruns this work. My first pass sampled the front of each file and put HCA near 5%. The real figure is 40.9%, eight times higher. HCA's files sort their contents by pricing method, and the chargemaster-linked lines sit in the back half of files that run past a gigabyte. Read the whole file or don't quote the number. The other sampling caveats live in the fine print at the bottom.
Picture one employer health plan whose contract with a Community Health hospital pays 70% of billed charges for outpatient surgery. In January the hospital raises its chargemaster 8%. No insurer signed off on that decision. The plan's cost for the same surgery rose 8% that morning anyway. Now multiply that across four of every five Community Health commercial rates.
| Operator | Commercial revenue (FY2025 10-K) | Revenue on chargemaster-linked contracts |
|---|---|---|
| CYH | $5,975M of $12,485M total (10-K) | ~$4.1–4.6B, roughly a third of total revenue |
| UHS | $4,902M of $17,365M total (10-K) | ~$3.8B, roughly 22% of total revenue |
| HCA | $36,968M of $75,600M total (10-K) | ~$15.1B if the sampled share holds fleet-wide, roughly 20% |
These figures state scale, not point estimates; the counting caveats are in the fine print. Exposed revenue means revenue that reprices through the chargemaster mechanism. Whether any of it goes away depends on the pressure paths below.
HCA appears in this table and also sits on my scoreboard: Issue 1 called HCA long, a bet that the stock beats the healthcare sector fund XLV, and that call is still open. The two coexist. The call rides a dated Medicare payment rule, while this repricing risk is commercial and arrives market by market on no schedule.
Tenet is the strange row in the table, and the strangeness is the finding. Eight of the ten Tenet hospitals I sampled publish files in the required format, carrying the required attestation that the file is true, accurate, and complete, and containing zero payer-negotiated rates. Detroit Receiving's file lists 8,147 billable items and no insurer rate for any of them. West Boca lists 10,981 items, also with none. The regulation (45 CFR 180.50(b)(2)(ii)) lists payer-specific negotiated charges among the elements the file must contain.
Correction, July 24, 2026: this paragraph originally cited 45 CFR 180.50(b)(3), a paragraph that does not exist in the current regulation. The correct provision is 180.50(b)(2)(ii). The requirement described is unchanged.
Maybe the real data lives somewhere else? I checked. Each hospital must publish a pointer file at a standard address on its own domain (for example dmc.org/cms-hpt.txt), naming its official price file. All eight pointers lead to the empty files. Two legacy pointers are dead links, and one hospital system published no pointer at all when I checked on July 6, 2026. I re-pulled all eight files on July 19, 2026, and nothing had changed.
On paper the penalty framework has teeth. A hospital that ignores a correction order faces daily fines under 45 CFR 180.90, up to $5,500 a day at large hospitals. CMS says automation now runs more than 200 comprehensive file reviews a month. Now the output side: the enforcement-actions list named 28 hospitals in four years, and both 2026 notices went to the same facility. Two hundred reviews a month, two notices a year.
Congress is the live pressure path. H.R. 9393, the Lower Costs, More Transparency Act of 2026, would write price transparency into the Social Security Act and extend it to labs, imaging, and surgery centers. The committee's chair and ranking member sponsor it together, and the subcommittee passed it by voice vote on June 25, 2026. The full committee took it up in a two-day, 29-bill amendment-and-vote session (a markup, in committee language). On July 21, 2026, it approved H.R. 9393, as amended, by a roll call of 45 to 0, and squeezed the companion wall-posting bill, H.R. 9390, through 24 to 21. The amended text codifies the disclosure rules, extends them to labs, imaging, and surgery centers, and adds insurer disclosure requirements on top.
No probability goes on my scoreboard for a vote that already happened. What stands on the record is the standing order from the bottom line, and the 45-to-0 vote moves its first tripwire, a House floor vote, from someday to plausibly this Congress. Floor scheduling belongs to leadership, and I put no date on it. Unanimity tells you something all the same: hospital price transparency now has no organized opposition inside the committee that writes health law.
A committee vote advances a bill; it does not reprice a contract. A statute still runs through the House floor, the Senate, and rulemaking before a single rate changes, and the penalty channel produces two notices a year. That is why the short waits. There is also still no price reaction to trade against: the files drew no press coverage, and I can find no sell-side note carrying an operator-level figure. The market has not read these files. That silence is the opportunity and the risk in one line.
The hidden escalator era is ending. For decades, chargemaster inflation quietly grew commercial hospital revenue without a single renegotiation, and nobody outside the contracts could measure it. As of January 2026 the exposure is public arithmetic. A mechanism that worked because it was invisible does not work the same once anyone with a laptop can count it.
Insurers just got a free audit of their own contracts. Any payer can now read its chargemaster-linked share at every hospital it contracts with, and its competitors'. The 2027 renewal cycle is the first one negotiated with both sides holding these files, and the leverage shifted toward whoever pays. Expect conversion pressure to show up at renewal cadence, market by market, not overnight.
The employers behind the insurers carry the real bill. Most commercial members sit in self-insured plans, so charge-linked pricing flows straight to employer plan sponsors. Those sponsors owe fiduciary duties, and an exposure that used to require a subpoena to see now requires a download. That is the slow-burning pressure path, and it does not need Congress.
Watch the operators migrate. HCA's spread, 3% linked in one market and 61% in another, shows that chargemaster-linking is a choice made market by market, not an industry constant. As pressure builds, expect hospital commentary about "rate structure modernization" and fixed-rate conversion. Every point of conversion is margin leaving the highest-linked operators first.
Enforcement is the swing variable. At two penalty notices a year, publishing an empty file costs nothing, and Tenet's files demonstrate that operators know it. A statute with teeth changes the arithmetic for every row in my table. That is why the standing order's first tripwire is the statute, not the regulator.
One call is open, from Issue 1: long HCA against the sector fund XLV, on the CY2027 outpatient payment proposal. The entry is the July 6, 2026 close of $417.07, the first trading session after CMS posted the rule. At the July 17 close of $371.18, the call stands at -11.0%, which is 10.5 percentage points behind XLV, with 9 of the 21 trading days in its grading window elapsed. The running tally lives on the calls record.
Most of that drawdown came on July 14. HCA pre-announced second-quarter results and cut full-year guidance because more of its patients are showing up uninsured, a roughly $400 million pre-tax hit in the quarter. That is an insurance-mix problem, not an outpatient-rule problem, but money is money and the mark is the mark. The rule side actually strengthened. The published text (CMS-1850-P) cuts payment for drugs bought through 340B, a federal discount program open only to nonprofit and government hospitals, and hands the entire $4.85 billion back as an 8.44% rate increase on everything else. For-profit hospitals cannot hold 340B status, so they skip the cut and collect the raise; the rule's own impact table puts them at +10.6%. For HCA that is worth roughly $400 to 600 million a year, about the size of one quarter's uninsured-mix damage. The call is vindicated if the November final rule keeps that trade. It fails if the rule takes the milder alternative, a court blocks it before January 1, 2027, or the uninsured mix keeps deteriorating. HCA reports July 24, 2026.
Three numbers in Issue 1 were wrong. Corrected against the published rule text: the for-profit impact is +10.6%, not 7.4%. The drug-payment cut is $4.85 billion, not $4.55 billion. The rate offset is 8.44%; the 8.14% I printed belongs to the rule's alternative scenario. Issue 1 also opened two calls it withdrew the same day, a short on Addus and a long on Molina, both voided on the calls record with no effect on any graded number.
Genetic testing: the squeeze is real, the target moved. UnitedHealthcare became the third insurer since June to tighten genetic-test coverage, capping lung-cancer gene panels at 50 genes and naming Signatera, Tempus, Caris, and Galleri tests as unproven, effective August 1. Issue 1 pointed at Quest and Labcorp; the named tests belong to Natera, Tempus, and Caris. Watch denial rates in third-quarter reporting.
RadNet: trigger hit, hold for November. The proposed physician fee schedule (CMS-1848-P) spares imaging this cycle: radiology +2%, imaging centers +4%, no across-the-board productivity cut. The November final rule can still rework the cost-allocation math, so this stays a watch.
Home health: the rule came in friendly. The CY2027 proposal (CMS-1844-P) raises payment 2.4% with no new permanent cut, good news for Pennant and Addus. Aveanna gets the same rule plus a seller: one private-equity holder sold 11 million shares in June, reported in a way that looked like three separate sellers but wasn't. That is share supply, not information; about 12.1 million shares remain.
Evolent: the footprint keeps growing. Molina Illinois routes advanced-imaging and cancer-care approvals through Evolent starting September 1, following Kentucky in July. Volume accrues to Evolent; paperwork accrues to imaging and oncology providers.
Passed on: the Medicare GLP-1 copay program and four insurer policy bulletins. The White House announced the GLP-1 deal in November 2025 and Lilly already rose 7% on the Medicare news, so buying in July buys the consensus at the top of its news cycle. The bulletins looked strong until read: they publish monthly, they cut both ways, and they mostly touch self-insured plans, where savings flow to employers rather than insurers.
The 29 files are every file that came back readable from the operators' own published indexes on July 3, 2026, re-verified July 6 and July 19. Rate lines that don't identify their insurance class are excluded: 22% of lines at HCA, 30% at Community Health. If every excluded Community Health line were fixed-dollar commercial, its 81.6% would fall to roughly 57%; the same worst case takes HCA from 40.9% to roughly 32%. The error can also run upward. My count weights every rate line equally; dollar-weighting would need claims volumes that are not public. Community Health's revenue bucket includes workers' compensation, so I trim it 5% to 15% before applying shares. Using each company's lowest and highest hospital instead of its average gives $2.7–5.6 billion at Community Health and $2.6–4.6 billion at Universal. HCA's $15.1 billion extrapolates ten hospitals across about 190; treat it as an order of magnitude. A rate line counts as chargemaster-linked when its methodology field says percent-of-charges or its rate is a stated percent of billed charges.
I track 50-plus primary regulatory and payer sources; every claim above links to its document, and I disclose undated items as undated.
I grade every call from the close of the first trading session after its evidence document became public; the document's date sets the entry, never the issue date. Grading runs against XLV in the called direction, I backdate nothing, and I correct wrong calls in the open.
I publish 10 to 12 issues a year, on no set schedule.